Massive Hemoptysis: An Update on the Role of Bronchoscopy in Diagnosis and Management

L. Sakr  H. Dutau
Thoracic Endoscopy Unit, Sainte-Marguerite University Hospital, Marseille, France

Introduction

Hemoptysis is a frequently encountered symptom in a pulmonologist's practice, with a clinical spectrum ranging from blood-streaked sputum to major bleeding with ensuing respiratory compromise and hemodynamic instability. ‘Massive hemoptysis’, although accounting for a minority of cases, should always be considered as a life-threatening condition that requires timely and effective management. Once airway protection and volume resuscitation are ensured, bronchoscopy plays a pivotal role with regard to localization of the anatomic site of bleeding, isolation of the involved airway, control of hemorrhage and treatment of the underlying cause of hemoptysis in case of visible endoluminal lesions. In this article, we will review the definition, etiology, pathophysiology, assessment and management of massive hemoptysis, with special focus on the essential role of bronchoscopy as a diagnostic and therapeutic tool.

Definition

Although massive hemoptysis is always regarded as a potentially lethal condition, there is no clear consensus on its precise definition. The volume of expectorated
blood has often been used to define episodes of massive hemoptysis, but no uniform cutoff value is agreed upon in the literature [1]. Amounts of expectorated blood ranging from 100 ml/24 h to more than 1,000 ml/24 h [2–19] have been proposed to define massive hemoptysis. Other terms, such as ‘major’ hemoptysis (≥ 200 ml/24 h) [4, 14], severe hemoptysis (≥ 150 ml/12 h) [3] and >400 ml/24 h in Khalil et al. [19]) and ‘exsanguinating hemoptysis’ [11] (≥ 1,000 ml total or ≥ 150 ml/h) have also been employed to describe the extent of bleeding. Mal et al. [12] described ‘life-threatening’ hemoptysis when bleeding occurred at a rate of at least 200 ml/h in a patient with normal or nearly normal lung function, or at least 50 ml/h in a patient with chronic respiratory failure, or when more than 2 episodes of moderate hemoptysis (at least 30 ml) occurred within 24 h in spite of the administration of intravenous vasopressin. Others have used this term to describe less severe bouts of hemoptysis, with a bleeding rate of ≥ 200 ml/24 h [15], up to ≥ 600 ml/24 h [5].

Lack of consensus regarding the cutoff volume, unreliable estimation of expectorated volume and the arbitrary use of this criterion regardless of all the other major determinants of morbidity and mortality, such as the rate of bleeding, the patient’s ability to maintain patent airways, and the extent and severity of cardiopulmonary comorbidities, have led to the use of a ‘magnitude-of-effect’ definition of massive hemoptysis [1, 20]. This more relevant definition relies on the main clinical consequences of hemoptysis: airway obstruction and hemodynamic instability. Examples of such a definition have included hemoptysis requiring transfusion [6], hospitalization [21], intubation [13, 19] or causing aspiration and airway obstruction [11], hypoxemia (PaO₂ < 8 kPa or 60 mm Hg) [16] or death [21].

### Brief Anatomy Recall

Massive hemoptysis usually originates from the high-pressure bronchial circulation (90%) [22]. Less frequently, the aorta (aortobronchial fistula, ruptured aortic aneurysm) or nonbronchial systemic circulation (intercostal arteries, coronary arteries, thoracic arteries originating from the axillary and subclavian arteries and the upper and inferior phrenic arteries) may be the source of bleeding (5%). In a minority of cases, massive hemoptysis may arise from the pulmonary vessels (5%) [23].

The bronchial arteries originate from the descending aorta, at the level of the 3rd–8th thoracic vertebral body levels, most often at the T5–T6 level. Wide anatomical variations of the numbers and sites of origin of the bronchial arteries have been described in healthy individuals. The most common pattern (almost 40% of patients) is a single right bronchial artery with 2 left bronchial arteries arising at the T5–T6 level. About 20% of bronchial arteries have an aberrant origin from other systemic nonbronchial arteries. In 5% of patients, a spinal artery originates from a bronchial artery [24].

In chronic inflammatory or infectious lung diseases, many alterations in vascular anatomy may occur. Enlargement and marked tortuosity of bronchial arteries, and increased arterial blood flow have been observed. In addition, vascular anastomoses between bronchial arteries and pulmonary veins, usually present in normal lungs, may become prominent, and new collaterals may develop. These pathological changes can account for an increased risk of bleeding and more complex vascular interventional procedures [25].

### Etiology

The most common causes of massive hemoptysis are listed in table 1. Currently, bronchiectasis, tuberculosis, mycetomas, necrotizing pneumonia and bronchogenic carcinomas are the main underlying conditions [5, 9, 12, 13, 15, 26, 27] (table 2). Although tuberculosis accounts for fewer cases of massive hemoptysis in the recent literature [9, 13], it remains a frequent etiology in areas with a high prevalence of the disease, such as Africa and China [5, 15]. In a series of 62 Chinese patients who underwent bronchial arterial embolization for massive hemoptysis (≥ 600 ml/24 h) between 2000 and 2005, the underlying cause was an old tuberculosis in 34 (55%) subjects, bronchiectasis in 14 (23%), mycetoma in 5 (8%), lung cancer in 4 (6%), necrotizing pneumonia in 4 (6%), and an arteriovenous malformation in 1 (2%) [5]. Knott-Craig et al. [15] found tuberculosis as the underlying disease in 85% (88/103) of patients who presented with massive hemoptysis in a South African university hospital.

In most other recent studies, however, bronchiectasis accounted for the majority of cases of massive hemoptysis. In a retrospective study from Singapore, where 29 patients were treated for massive hemoptysis in an intensive care unit, bronchiectasis was found in most cases (n = 19, 66%), while mycetoma (n = 4, 14%), active tuberculosis (n = 3, 10%), tumor (n = 2, 7%) and diffuse alveolar hemorrhage (n = 1, 3%) were diagnosed in the remaining patients [13]. Similarly, in a recently published French series
of 196 patients admitted to an intensive care unit for severe hemoptysis between January 1999 and December 2001 (median cumulative amount of blood loss averaging 200 ml on admission), bronchiectasis was the leading underlying cause (n = 78, 40%), followed by lung cancer (n = 33, 17%), active tuberculosis (n = 27, 14%) and mycetoma (n = 14, 7%) [26].

In a cohort of 57 Austrian patients presenting with life-threatening hemoptysis from January 2000 to January 2004, lung cancer (n = 20, 35%) was the most common diagnosis, followed by tuberculosis (n = 13, 23%), cryptogenic etiology (n = 9, 16%), metastatic disease (n = 6, 10.5%), bronchiectasis (n = 5, 8.5%) and vascular malformations (n = 4, 7%) [16]. Cystic fibrosis, most often associated with bronchiectasis, has become a more common etiology of massive hemoptysis because of the longer survival of affected patients [6].

Although the bronchial circulation accounts for most cases of massive hemoptysis, pulmonary arteries (PAs) remain the source of bleeding in a substantial number of patients. Massive bleeding may arise from the PA circulation in several pathologic processes, such as necrotizing pulmonary infections (active tuberculosis [23, 28, 29]), pulmonary abscess [23, 28, 29], mycetoma [23, 29]), necrotic cavitary lung carcinoma or Hodgkin lymphoma [23, 28, 29], vasculitis (Behçet disease or Hughes-Stovin syndrome) [23, 28, 30], trauma from a PA (Swan-Ganz) catheter [31, 32], and pulmonary arteriovenous malformation [29, 33, 34]. In most patients with infectious or inflammatory etiologies, hemoptysis is due to erosion of small friable PA branches located within the peribronchial tissue. Peripheral PA pseudoaneurysms may also develop in such conditions and become a source of massive bleeding [35]. Other causes of massive PA hemorrhage have included bronchovascular fistulization in the context of lung transplant-related airway anastomotic ischemic or infectious necrosis [36–38], Rasmussen’s aneurysms [39, 40], and diagnostic or therapeutic procedure-related bleeding (e.g. transbronchial lung biopsy [41], endobronchial brachytherapy [42] and lung radiofrequency ablation [43]).

Although alveolar hemorrhage is a well-recognized cause of hemoptysis, it rarely presents with massive bleeding since the alveoli can accommodate a large amount of blood. Curiously, despite extensive diagnostic workup, cryptogenic massive hemoptysis has been reported in 11–19% of cases in the recent literature [12, 26, 27, 44].
Epidemiology and Natural History

Life-threatening massive hemoptysis accounts for only a minority of episodes of hemoptysis, ranging from 5 to 15% across studies [1, 4, 9, 16, 45]. In lung cancer patients, hemoptysis occurs in 20% of subjects at some time during their clinical course, with massive episodes developing as the terminal event in 3% [46]. In an observational cohort study of the US National Cystic Fibrosis Patient Registry between the years 1990 and 1999, 4.1% of patients were treated for massive hemoptysis [6].

However, associated mortality is rather high and has been shown to be mainly related to the rate of bleeding. Crocco et al. [7] reported a 71% mortality rate in patients who lost ≥600 ml of blood in 4 h, a mortality rate of 22% in patients with ≥600 ml within 4–16 h, and of 5% in those with 600 ml of hemoptysis within 16–48 h. When considering patients who lost more than 600 ml of blood within 16 h, mortality rates were shown to exceed 75% in those deemed inoperable, 78% in operable patients who were not operated on because of patient refusal or delay in management as compared to 23% in those who underwent surgical resection. Corey and Hla [4] reported a 58% mortality rate in patients who lost ≥1,000 ml of blood in 24 h compared to 9% in those with bleeding rates <1,000 ml/24 h.

In more recent studies, mortality rates for massive hemoptysis have ranged from 9 to 38% [9, 12, 13, 15, 47]; the highest (38%) mortality rate was reported by Hirshberg et al. [9] in a series that included a high proportion of patients with advanced carcinoma [9]. In a most recent single-center study comparing the management of massive hemoptysis (≥600 ml/24 h) and outcomes in a recent 5-year period (2000–2005) with those from the previous 5 years (1995–1999), the in-hospital mortality rate was 0% in the former group compared to 15% in the latter. A multidisciplinary approach in favor of bronchial artery embolization (BAE) as first-line therapy was the major change in the recent 5-year period. Surgery was undertaken only when BAE failed to stop the bleeding. Old tuberculosis and bronchiectasis were the main underlying diseases in that series [5].

Several studies have tried to establish prognostic features for poor outcome in patients with massive hemoptysis. Bleeding rate of at least 1,000 ml within a 24-hour period, aspiration of blood in the contralateral lung, massive bleeding requiring single-lung ventilation and bronchogenic carcinoma as an underlying etiology have all been associated with higher mortality [1, 4, 8]. Patients seemed to fare better when tuberculosis, bronchitis or bronchiectasis were responsible for the massive hemoptysis [4]. In a recent study, however, bronchiectasis as an underlying cause was associated with a higher rate of recurrence of hemoptysis in a series of patients treated by BAE [48]. In cancer patients, non-tumor-related hemoptysis was associated with better survival in comparison with tumor-related bleeding, following endovascular management [49]. Van den Heuvel et al. [50] reported higher mortality rates in patients who experienced recurrent bleeding following BAE for massive hemoptysis. In addition, they identified the following risk factors for recurrence of hemoptysis: (1) residual mild bleeding beyond the first week after BAE; (2) blood transfusion before the procedure, and (3) diagnosis of aspergilloma as the underlying etiology. On the other hand, patients with active tuberculosis undergoing medical treatment experienced significantly fewer recurrent bleeding events. Thereafter, the same group prospectively evaluated these risk factors as selection criteria for surgical management following BAE. Low-risk patients (≤1 risk factor) were

Table 2. Underlying etiology of massive hemoptysis in recent studies

<table>
<thead>
<tr>
<th>Study</th>
<th>Year</th>
<th>Country</th>
<th>Patients</th>
<th>Underlying cause of hemoptysis, %</th>
<th>bronchiectasis</th>
<th>TB</th>
<th>lung CA</th>
<th>mycetoma</th>
<th>pneumonia</th>
<th>idiopathic</th>
<th>other</th>
</tr>
</thead>
<tbody>
<tr>
<td>Shigemura et al.</td>
<td>2000–05</td>
<td>China</td>
<td>62</td>
<td>23</td>
<td>55</td>
<td>6</td>
<td>8</td>
<td>6</td>
<td>16</td>
<td>17.5</td>
<td></td>
</tr>
<tr>
<td>Valipour et al.</td>
<td>2000–04</td>
<td>Austria</td>
<td>57</td>
<td>8.5</td>
<td>23</td>
<td>35</td>
<td>11</td>
<td>14</td>
<td></td>
<td>3</td>
<td></td>
</tr>
<tr>
<td>Fartoukh et al.</td>
<td>1999–01</td>
<td>France</td>
<td>195</td>
<td>40</td>
<td>14</td>
<td>17</td>
<td>7</td>
<td>3</td>
<td></td>
<td>9</td>
<td></td>
</tr>
<tr>
<td>Ong and Eng</td>
<td>1997–01</td>
<td>Singapore</td>
<td>29</td>
<td>66</td>
<td>10</td>
<td>7</td>
<td>14</td>
<td></td>
<td></td>
<td>3</td>
<td></td>
</tr>
<tr>
<td>Hsiao et al.</td>
<td>1988–00</td>
<td>USA</td>
<td>28</td>
<td>57</td>
<td>7</td>
<td>14</td>
<td></td>
<td>7</td>
<td>14</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Revel et al.</td>
<td>1995–99</td>
<td>France</td>
<td>80</td>
<td>31</td>
<td>19</td>
<td>11</td>
<td>7.5</td>
<td>10</td>
<td>14</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mal et al.</td>
<td>1985–97</td>
<td>France</td>
<td>46</td>
<td>9</td>
<td>50</td>
<td>4</td>
<td>2</td>
<td>4</td>
<td>22</td>
<td>9</td>
<td></td>
</tr>
<tr>
<td>Knott-Craig et al.</td>
<td>1983–90</td>
<td>S. Africa</td>
<td>120</td>
<td>85</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
not considered surgical candidates, while high-risk subjects (2–4 risk factors) underwent surgery if considered safe according to lung function parameters. No deaths occurred among low-risk or high-risk patients who underwent surgery following embolization. On the other hand, 2/7 high-risk subjects who were deemed inoperable died during follow-up [51].

**Diagnosis**

Diagnostic workup for massive hemoptysis should be undertaken as soon as airway protection and hemodynamic status are assessed and stabilized. If possible, a careful history and clinical examination should be performed in order to rule out nonpulmonary causes of bleeding such as epistaxis and hematemesis.

There is no consensus on the optimal diagnostic approach to massive hemoptysis. However, several studies have explored the clinical utility of performing a chest radiograph, a computed tomography (CT) scan and bronchoscopy before definitive treatment strategies. Chest radiography can identify the site of bleeding in 33–82% of cases of massive hemoptysis [9, 13, 17, 19, 52, 53], and may reveal the underlying cause in 35% [19], most of which including either tuberculosis or tumors. Although chest radiographs are rarely normal in episodes of massive hemoptysis, normal findings have been shown to suggest bronchiectasis as the cause of bleeding [19, 52].

CT might be superior to chest radiography, and comparable to bronchoscopy for detecting the site of bleeding in massive hemoptysis, with correct localization in 70–88.5% of cases [17, 19, 53]. In addition, CT is much more efficient than bronchoscopy for determining the cause of bleeding (60–77 vs. 2.5–8%) [17, 19]; this has already been demonstrated in earlier studies [27, 54, 55]. Moreover, by showing possible extrapulmonary causes of hemoptysis, such as false aortic aneurysms [19], CT can obviate the need for bronchial arteriography. While some authors suggest that CT can replace bronchoscopy as a first-line investigational approach in patients with large (<300 ml/24 h) or massive hemoptysis (>300 ml/24 h) because of its higher diagnostic yield [19], others advocate it as complementary to fiber-optic bronchoscopy (FOB) for bleeding site identification [17]. Hsiao et al. [52] showed that radiographic studies (chest radiography and CT) are highly informative to guide the approach to bronchial artery embolization, and therefore obviate the need for FOB in patients with hemoptysis of known etiology, not requiring airway management. In addition, high-resolution CT scans might provide prognostic information since a correlation has been found between the extent of lobar involvement on high-resolution CT and the daily and cumulative amount of bleeding [17]. Recently, multidetector CT has been proven valuable for a precise delineation of bronchial and nonbronchial systemic arteries. Yoon et al. [56] were able to identify all 31 bronchial arteries and 16 of 26 (62%) nonbronchial systemic arteries causing hemoptysis, using a 16-detector row CT. Interestingly, they were also able to trace (23/31, 75%) most of the bronchial arteries causing bleeding from their origin to the hilum while only 1 of 9 (11%) bronchial arteries not causing hemoptysis was traceable. In a study by Remy-Jardin et al. [57], multidetector CT allowed more accurate identification of bronchial and nonbronchial systemic arteries in comparison with conventional angiography. CT features consistent with nonbronchial systemic arterial supply were (1) pleural thickness of ≥3 mm near a parenchymal opacity, and (2) enhancing vessels within the extrapleural fat layer [58]. Moreover, in a recent study, multidetector CT was proven effective for accurate identification and early management of massive hemoptysis of PA origin [23]. Signs of PA bleeding consisted of the following: (1) PA pseudoaneurysm, or (2) aneurysm, or the presence of a PA in the inner wall of a cavitory lesion. In addition, multidetector CT findings of associated bronchial arterial hypertrophy predicted the need for simultaneous bronchial artery and PA embolization [23].

Despite these important advantages specific to CT, this imaging technique has several limitations. Indeed, in unstable patients, in patients with active bleeding requiring endobronchial management, and in patients with bilateral lung abnormalities in whom radiographic bleeding localization might be challenging, FOB appears to be the optimal approach prior to definitive endovascular treatment.

FOB identifies the site of bleeding in 73–93% of episodes of massive bleeding [17, 19, 52]. Its diagnostic yield for bleeding localization has been shown to be significantly lower in cases of mild or moderate hemoptysis [27, 55]. The optimal timing for a diagnostic FOB in hemoptysis remains a controversial issue [1, 59]. Although the likelihood of visualizing the site of bleeding was significantly better with early versus delayed FOB, the timing of the procedure did not alter therapeutic decisions or clinical outcome in nonmassive hemoptysis [1, 59–61]. It is crucial, however, to recognize the limitations of FOB in massive, life-threatening hemoptysis. Interventional pulmonologists should not rely on flexible bronchoscopes in such situations, as this will delay timely and effective
management. Rigid bronchoscopy is more efficient at safeguarding airway patency, preserving ventilation, and allowing better clearance of the airways, therefore improving visualization [18]. However, a flexible fiber-optic bronchoscope can be introduced through the rigid scope as it provides easier access to the upper lobes and peripheral bronchi, thus allowing optimal exploration of the bronchial tree [62].

**Management of Massive Hemoptysis**

The initial approach for management of massive hemoptysis involves protection of the airways and volume resuscitation [1, 62]. If the bleeding side is known, the patient should be placed in a lateral decubitus position, with the bleeding side down in order to prevent aspiration into the unaffected lung (fig. 1). The patient should be transferred to an intensive care unit where careful monitoring and effective management can be provided. If hemodynamic or respiratory status is compromised, urgent rigid bronchoscopy should be attempted by a skilled physician, as it is the most efficient means of clearing the airways from blood clots and secretions, ensuring effective tamponade of the bleeding airway and safe isolation of the nonaffected lung, thereby preventing asphyxia and preserving ventilation.

However, not all bronchoscopists are trained in rigid bronchoscopy. Moreover, a bronchoscopist is not always readily available in the event of massive hemoptysis. In such circumstances, the patient should be intubated with a large-caliber endotracheal tube (preferably size 8 or more), and FOB should be immediately performed, mainly to suction blood clots and secretions. Alternatively, once the airways are cleared, unilateral intubation can be performed to protect the nonbleeding lung from aspiration and to allow effective ventilation while awaiting definitive treatment strategies. However, it is not advisable to selectively intubate the right main bronchus in case of bleeding originating from the left lung as this procedure would occlude the right upper lobe bronchus, further compromising gas exchange. Instead, tracheal intubation can be performed, followed by insertion of a balloon catheter besides the endotracheal tube through the vocal cords, with subsequent introduction into the left main bronchus under bronchoscopic visualization. Although double-lumen intubation also allows isolation of the bleeding lung while preventing aspiration into the unaffected lung, this procedure requires highly trained medical personnel, and should only be performed after clearing the airways. Once hemodynamic and respiratory conditions are stabilized, urgent endovascular therapy should be considered.

**Bronchoscopic Treatment**

When expertise is available, bronchoscopic treatment strategies ensure adequate control of bleeding, therefore contributing to stabilization of the patient’s hemodynamic status and respiratory parameters. They are most often temporary measures for early management; however, in some circumstances, bronchoscopic management provides a long-lasting hemostatic effect.

First, a skilled bronchoscopist should be aware of basic strategies to manage procedure-induced bleeding in the endoscopy suite. Such strategies include performing biopsies in dependent areas of the lung, whenever possible, so as to facilitate bleeding control. Following a transbronchial biopsy, the bronchoscope should be kept in a wedged position, in order to ensure effective tamponade of the bleeding mucosa. Suctioning and frequent scope repositioning should be kept to a minimum between sampling to avoid dislodging freshly formed blood clots. Once all desired biopsies are performed, wedging should be maintained for 3–5 min, following which the bronchoscope is withdrawn carefully and gradually, and suction is applied only at a certain distance from the biopsy site. If vision is obscured during the procedure, the bronchoscope can be gently rubbed against tracheal cartilage and/or cold saline may be applied locally [63]. If massive bleed-
Rigid bronchoscopy clearly has merits with regard to airway assessment and management in patients with massive life-threatening hemoptysis. It is very efficient at securing airway patency and safeguarding ventilation, thereby preventing asphyxia. It allows better suction of blood clots and secretions through its large working channel, and improved visualization of the airways. It also provides effective tamponade of accessible bleeding sites, and allows isolation of the nonaffected lung. In addition, bronchial blocking using a variety of endoscopic devices – as described in detail below – is much easier to perform through the wider lumen of a rigid bronchoscope. The latter therefore allows stabilizing a patient’s hemodynamic and respiratory conditions before proceeding with further diagnostic or therapeutic interventions. If the underlying lesion is endoluminal, whether in the central airways or in more peripheral bronchi within the reach of the rigid scope, the latter allows further management, including local coagulation therapy (laser, electrocautery, argon plasma coagulation, APC), as outlined below. Therefore, rigid bronchoscopy is safer and much more efficient than its flexible counterpart at controlling hemoptysis in patients with compromised airways. However, FOB might be useful as a complementary tool for optimal inspection of the upper lobes and peripheral airways.

Whether a rigid bronchoscope should be available in every bronchoscopy suite remains a controversial issue. More importantly, the main question is whether training in rigid bronchoscopy should be offered on a larger scale, an example of which would consist of introducing such technical skills into respiratory fellowship programs. A recent survey conducted among US respiratory/critical care fellowship directors revealed that the presence of an interventional pulmonologist on staff was associated with increased availability of advanced procedural training, including rigid bronchoscopy-related skills. However, only 41% of the training programs which offered rigid bronchoscopy procedures allowed fellows to reach the targeted number (20 procedures) to obtain competency [64]. Another survey conducted among Canadian respiratory physicians in 2002 showed that only 20.8% of specialists performed rigid bronchoscopy [65]. Training in rigid bronchoscopy requires availability of a proficient interventional pulmonologist in the service as well as performance of a sufficient amount of procedures in order to develop the required skills. In addition, following the training period, regular performance of rigid bronchoscopy is required in order to maintain and improve such skills, especially when using rigid bronchoscopy in urgent settings such as management of massive hemoptysis. Availability of an operating theater, an anesthesiologist and good and effective collaboration with thoracic surgeons are necessary as well. Such requirements are difficult to meet in most hospital centers; therefore, not all bronchoscopists need to train and become proficient in rigid bronchoscopy.

In the following discussion, we present an overview of the various bronchoscopic devices and treatment strategies used in clinical practice (table 3). Again, we would like to emphasize that, although some of the following procedures can be performed by FOB, rigid bronchoscopy is more efficient and much safer in the hands of well-trained personnel.

Cold-Saline Lavage

The first case of endobronchial irrigation with cold saline for the early management of hemoptysis was reported in 1980 [18]. Lavage with normal saline at 4°C in 50-ml aliquots (average volume of 500 ml, range 300–750 ml) stopped the bleeding in 23 patients with massive hemoptysis (≥600 ml/24 h), obviating the need for emergency thoracotomy. A rigid bronchoscope was used during the session, and was introduced in an alternate manner on the nonbleeding side in order to isolate the lung and enable gas exchanges, and subsequently on the bleeding side to evacuate clots and large amounts of blood, and to perform local irrigation. One patient experienced transient sinus bradycardia during the procedure. Only 2 subjects suffered subsequent episodes of massive bleeding 3 and 10 days later, and required further lavage. All patients underwent subsequent medical or surgical therapy after stabilization, and all were discharged free of hemoptysis [18, 66].

Although cold-saline irrigation is also feasible with a FOB, the rigid scope has better suction capacity, thus enabling a better view of the involved area.

Topical Vasoconstrictive Agents

Local instillation of topical vasoconstrictive agents in the bleeding airway can be effective in mild to moderate hemoptysis following bronchial brushing and biopsy procedures [67–69]. This approach is not useful for massive bleeding, however, because the drug is diluted and washed away [70]. Interestingly, in a recent study evaluating hemostatic tamponade therapy for the management of massive hemoptysis, 13 of 76 (17%) patients were excluded because of prior response to conservative therapy consisting of
topical epinephrine (1:20,000) and/or cold-saline lavage, therefore obviating the need for further tamponade [16]. However, some studies have reported high plasma levels following endobronchial application of epinephrine [71], with significant cardiovascular effects namely acute hypertension and tachyarrythmias [72]. This observation prompted some investigators to use topical antidiuretic hormone derivatives, such as terlipressin and ornipressin, for their vasoconstrictive effect. Topical ornipressin proved as effective as adrenaline at promoting hemostasis but with significantly fewer hemodynamic adverse events [73]. In a trial comparing intravenous and endobronchial administration of terlipressin during bronchoscopy-induced bleeding, a similar hemostatic effect was observed for both routes; however, drug plasma levels were 251-fold higher and diastolic pressure was significantly increased following intravenous administration [67].

**Tranexamic Acid**

This antifibrinolytic drug administered via the oral or intravenous route is widely used for the treatment or prophylaxis of mucosal bleeding in patients with bleeding disorders or following major surgery [74]. Several case reports documenting its efficacy in controlling major hemoptysis in cystic fibrosis patients have recently been published. Wong et al. [75] reported successful management of recurrent hemoptysis with intravenous followed by oral tranexamic acid (TA) in a patient with cystic fibrosis and collateral vessels after repeated failure of BAE. Chang et al. [76] described a cystic fibrosis patient with recurrent episodes of major hemoptysis caused by multiple aberrant bronchial arteries. Repeated BAEs were only partially successful. TA was eventually started and controlled bleeding effectively for 5 months, until a recurrent episode prompted surgical resection. Graff [77] reported another successful trial of oral TA treatment in a cystic fibrosis patient after 12 previous BAE procedures had failed to control recurrence of hemoptysis. Further BAE was counter-indicated because of bronchial to spinal artery collaterals. Several attempts to stop TA were followed by recurrence of bleeding. The patient was therefore maintained on TA therapy for 13 months without adverse events.

Topical use of TA has also proven effective for several other indications. TA mouthwash has successfully controlled bleeding following oral surgery in anticoagulated patients [78, 79]. Intrapleural administration of TA in combination with the oral preparation has effectively reduced bleeding and transfusion requirements in patients with malignant mesothelioma presenting with hemothorax [80].

Topical administration of TA within the bronchial tree has been described only recently. Two patients experienced severe bleeding from malignant tumors following bronchoscopy. Bronchoscopic procedures consisted of transbronchial biopsy in one patient and electrocautery treatment of a visible endoluminal lesion in the other. Ensuing bleeding, which ranged from 600–750 ml, did not respond to initial conservative therapy (cold saline, epinephrine) but was successfully managed thereafter with endobronchial instillation of TA (500–1,000 mg). Bleeding stopped within seconds of application, and patients were discharged within a few days without recurrence of hemoptysis [81].

**Fibrinogen/Thrombin**

Endoscopic instillation of fibrinogen-thrombin combination in a series of 11 patients with severe hemoptysis (≥150 ml/12 h), in whom BAE was [75] contraindicated, unavailable or ineffective, has been described recently [10]. After local application of cold saline, epinephrine, or collapse of the bleeding bronchus through continuous suction, and drying of the airway thereafter with oxygen, the fibrinogen-thrombin combination was instilled through a catheter within an FOB. In addition, factor XIII and aprotinin were added to the mixture for better stabilization of the fibrin clot. This approach allowed immediate arrest of bleeding in all patients. Early recurrence of severe hemoptysis occurred in 2 patients, 6 h and 3 days after treatment, respectively, whereas late relapse occurred in 1 patient 12 months after the procedure.

In a previous study by Tsukamoto et al. [82], immediate control of massive bleeding was achieved in 6 of 10 patients treated with thrombin, and in all 9 patients managed with a fibrinogen-thrombin mixture. Short-term relapse of hemoptysis in the fibrinogen-thrombin group occurred in 3 patients, between 24 h and 14 days following the procedure. Bense [83] also reported 3 patients successfully treated with the fibrinogen-thrombin combination for hemoptysis, with 1 short-term relapse.

This approach seems promising as an initial strategy for the early management of massive hemoptysis while awaiting BAE, or as an alternative treatment when endovascular procedures cannot be performed for the reasons stated above. However, further clinical studies are needed before endorsing this treatment in massive hemoptysis.

**Balloon Tamponade**

The successful use of a Fogarty balloon catheter for endobronchial tamponade in life-threatening hemoptysis was initially described in 1974 [84, 85]. It was inserted...
### Table 3. Bronchoscopic treatment strategies for massive hemoptysis

<table>
<thead>
<tr>
<th>Treatment strategy</th>
<th>Studies</th>
<th>Bleeding severity</th>
<th>Patients</th>
<th>Immediate control</th>
<th>Short-term recurrence</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Cold saline</strong></td>
<td>Conlan et al. [18, 66] (1980)</td>
<td>≥600 ml/24 h</td>
<td>23</td>
<td>23/23 (100%)</td>
<td>2 patients (3 and 10 days)</td>
</tr>
<tr>
<td><strong>Topical vasoconstrive agents</strong></td>
<td>Tüller et al. [69] (2004)</td>
<td>see notes below¹</td>
<td>110</td>
<td>110/110 (100%)</td>
<td>no</td>
</tr>
<tr>
<td><strong>Balloons tamponade</strong></td>
<td>Hiebert et al. [84] (1974)</td>
<td>hemothysis with hemodynamic collapse ≥100 ml of blood loss</td>
<td>1</td>
<td>1 (100%)</td>
<td>no</td>
</tr>
<tr>
<td></td>
<td>Freitag et al. [86] (1994)</td>
<td></td>
<td>27</td>
<td>26/27 (96%)</td>
<td>1 patient (5 days)</td>
</tr>
<tr>
<td></td>
<td>Kato et al. [87] (1996)</td>
<td>1,500 ml in 10 h 600 ml/12 h, 300 ml/6 h, 100 ml/3 h</td>
<td>1</td>
<td>1 (100%)</td>
<td>no</td>
</tr>
<tr>
<td></td>
<td>Jolliet et al. [88] (1992)</td>
<td></td>
<td>3</td>
<td>3 (100%)</td>
<td>no</td>
</tr>
<tr>
<td><strong>Endobronchial stent placement</strong></td>
<td>Brandes et al. [89] (2008)</td>
<td>Hb drop from 10 to 5.8 g/dl in few weeks</td>
<td>1</td>
<td>1 (100%)</td>
<td>no</td>
</tr>
<tr>
<td><strong>Endobronchial spigot</strong></td>
<td>Dutau et al. [90] (2006)</td>
<td>massive hemoptysis</td>
<td>1</td>
<td>1 (100%)</td>
<td>no</td>
</tr>
<tr>
<td><strong>Oxidized regenerated cellulose</strong></td>
<td>Valipour et al. [16] (2005)</td>
<td>see notes below²</td>
<td>57</td>
<td>56/57 (98%)</td>
<td>6 patients (mild-moderate bleeding days 3–6)</td>
</tr>
<tr>
<td><strong>N-Butyl cyanoacrylate glue</strong></td>
<td>Bhattacharyya et al. [92] (2002)</td>
<td>prolonged (&gt;7 days) hemothysis</td>
<td>6</td>
<td>6 (100%)</td>
<td>1 patient at 1 month, mild hemoptysis</td>
</tr>
<tr>
<td><strong>Fibrinogen-thrombin</strong></td>
<td>de Gracia et al. [10] (2003)</td>
<td>severe hemothysis (≥150 ml/12 h)</td>
<td>11</td>
<td>11 (100%)</td>
<td>2 patients (6 h and 10 days) with severe relapse</td>
</tr>
<tr>
<td></td>
<td>Tsukamoto et al. [82] (1989)</td>
<td>massive hemothysis</td>
<td>9</td>
<td>9/9 (100%)</td>
<td>3 patients (24 h to 14 days) after fibrinogen-thrombin</td>
</tr>
<tr>
<td></td>
<td>Bense et al. [83] (1990)</td>
<td>massive hemothysis</td>
<td>3</td>
<td>3/3 (100%)</td>
<td>1 patient (&lt;14 days)</td>
</tr>
<tr>
<td><strong>Tranexamic acid</strong></td>
<td>Solomonov et al. [81] (2009)</td>
<td>750 ml (Pt #1), 600 ml (Pt #2)</td>
<td>2</td>
<td>2/2 (100%)</td>
<td>no</td>
</tr>
<tr>
<td><strong>Laser photocoagulation</strong></td>
<td>Edmondstone et al. [94] (1983)</td>
<td>&gt;1,000 ml in few hours</td>
<td>1</td>
<td>1/1 (100%)</td>
<td>no recurrence at 8 days</td>
</tr>
<tr>
<td></td>
<td>Shankar et al. [95] (1990)</td>
<td>6-week history of severe hemothysis recurrent hemothysis</td>
<td>1</td>
<td>0/1; not effective</td>
<td>no recurrence at 8 days</td>
</tr>
<tr>
<td></td>
<td>Hetzel et al. [96] (1991)</td>
<td>recurrent hemothysis</td>
<td>3</td>
<td>3 (100%)</td>
<td>1 patient (8 weeks), 1 patient (25 weeks), 1 patient dead 8 weeks not accurately described</td>
</tr>
<tr>
<td></td>
<td>Hetzel et al. [96] (1991)</td>
<td>recurrent hemothysis</td>
<td>24</td>
<td>16/24 (67%)</td>
<td>no</td>
</tr>
<tr>
<td><strong>Argon plasma coagulation</strong></td>
<td>Keller et al. [99] (2001)</td>
<td>recurrent massive hemothysis &gt;200 ml/24 h in 6, &gt;50–200 ml/24 h in 23</td>
<td>1</td>
<td>1 (100%)</td>
<td>no</td>
</tr>
<tr>
<td></td>
<td>Morice et al. [100] (2001)</td>
<td>not specified</td>
<td>29</td>
<td>29/29 (100%)</td>
<td>no</td>
</tr>
<tr>
<td><strong>Electrocautery</strong></td>
<td>Homasson [104] (1997)</td>
<td>not specified</td>
<td>56</td>
<td>42/56 (75%)</td>
<td>no recurrence at 4 weeks</td>
</tr>
<tr>
<td></td>
<td>Sutedja et al. [105] (1994)</td>
<td>not specified</td>
<td>4</td>
<td>4/4 (100%)</td>
<td>no recurrence at 4 weeks</td>
</tr>
</tbody>
</table>

¹ Bleeding persisting for 2 min of continuous suction, bleeding increasing in time or considered as major.
² >150 ml/h, or ≥150 ml on one occasion, plus clinical consequences such as impaired respiratory function with a PaO₂ <60 mm Hg.
<table>
<thead>
<tr>
<th>Long-term recurrence after endoscopic therapy</th>
<th>Definitive therapy</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>18 (medical), 5 (surgical)</td>
<td>vasoconstrictive drugs</td>
<td>transient bradycardia in 1 patient during cold irrigation</td>
</tr>
<tr>
<td>1 patient died of aspiration after pulling out tube himself</td>
<td>emergency surgery</td>
<td>bronchiectasis as underlying cause of life-threatening hemoptysis</td>
</tr>
<tr>
<td>see comments</td>
<td>BAE (12), surgery (11), radiation (5), medical (4)</td>
<td>balloon catheter left in place until definitive Tx (between 15 min and 1 week)</td>
</tr>
<tr>
<td></td>
<td>BAE balloon tamponade</td>
<td>balloon catheter removed 72 h after insertion</td>
</tr>
<tr>
<td></td>
<td>palliative radiotherapy</td>
<td>died without bleeding recurrence at 3 months</td>
</tr>
<tr>
<td>1 patient died of aspiration after pulling out tube himself see comments</td>
<td>palliative radiotherapy</td>
<td>died without bleeding recurrence at 3 months</td>
</tr>
<tr>
<td>1 patient died of aspiration after pulling out tube himself see comments</td>
<td>BAE</td>
<td>spigot removed 2 h after successful BAE</td>
</tr>
<tr>
<td></td>
<td>no hemoptysis-related death at 10 months</td>
<td>oxidized regenerated cellulose; BAE attempted in 6 patients with recurrent hemoptysis</td>
</tr>
<tr>
<td></td>
<td>no other recurrences on follow-up of 70–250 days</td>
<td>antibiotics (4 patients), anti-TB agents (2 patients)</td>
</tr>
<tr>
<td>1 patient (12 months)</td>
<td>BAE 3 patients; surgery in 1 after failure of BAE</td>
<td>simultaneous instillation of equal volumes of fibrinogen and thrombin</td>
</tr>
<tr>
<td>no other recurrences on follow-up of 11–60 months</td>
<td>medical therapy</td>
<td>instillation of fibrinogen and thrombin at different times</td>
</tr>
<tr>
<td>no other recurrences on follow-up of 2–36 months</td>
<td>TA (patient 1), surgery (patient 2)</td>
<td>simultaneous instillation of equal volumes of fibrinogen and thrombin</td>
</tr>
<tr>
<td>1 patient (3 Tx by week 40), 1 patient (4 Tx by week 25)</td>
<td>laser photocoagulation</td>
<td>patient 1 discharged after few days with no recurrence, patient 2 awaiting surgery; bronchoscopy-related hemoptysis in both</td>
</tr>
<tr>
<td>not accurately described</td>
<td>emergency tamponade with ETT, then elective surgery</td>
<td>patient with metastatic non-small-cell lung cancer; died on day 8 without recurrence of hemoptysis</td>
</tr>
<tr>
<td></td>
<td>Nd-YAG laser</td>
<td>hemangiopericytoma lower trachea, with profuse bleeding during laser Tx</td>
</tr>
<tr>
<td></td>
<td>APC</td>
<td>malignant etiology in all cases, 1 died after 8 weeks without recurrence</td>
</tr>
<tr>
<td></td>
<td>not accurately described</td>
<td>malignant etiology in all cases</td>
</tr>
<tr>
<td>1 patient (12 months)</td>
<td>APC</td>
<td>recurrence free at 10 months</td>
</tr>
<tr>
<td>no recurrence of bleeding at 97 days</td>
<td>APC</td>
<td>massive hemoptysis refractory to BAE; endobronchial nodules, bronchoalveolar lavage; cryptococcus</td>
</tr>
<tr>
<td></td>
<td>electrocautery</td>
<td>malignant etiology in most cases</td>
</tr>
<tr>
<td></td>
<td></td>
<td>both malignant and benign endobronchial lesions</td>
</tr>
<tr>
<td></td>
<td></td>
<td>malignant etiology in all cases</td>
</tr>
</tbody>
</table>
through a flexible fiber-optic bronchoscope in the right main bronchus, inflated and kept in place as an emergency measure in a hemodynamically unstable patient following bouts of severe hemoptysis. This enabled airway protection and resuscitation manoeuvres before surgical resection of lung tissue exhibiting severe bronchiectasis.

More recently, Freitag et al. [86] developed a double-lumen bronchus-blocking balloon catheter, usually inserted into the working channel of a flexible fiber-optic bronchoscope. The second lumen of the catheter allows administration of cold saline, vasoactive drugs or other topical agents. A detachable double valve at the proximal end of the catheter allows safe removal of the flexible fiber-optic bronchoscope without displacement of the balloon catheter. Balloon tamponade was successful in 26/27 patients who lost at least 100 ml of blood, and occlusion was feasible in main, lobar and segmental bronchi, and cavities. The catheter was kept in place between 15 min and 1 week, and was only deflated for a few minutes 3 times a day, in order to preserve mucosal viability and to check for bleeding recurrence. The catheter was left in position until patients underwent definitive therapy. Adverse effects consisted of lobar pneumonia in a patient whose catheter had been in place for 5 days, transient hoarseness in another patient because of granulation tissue on the vocal cords, and catheter migration in 3 patients, successfully managed by simple repositioning. Interestingly, bronchial artery embolization was facilitated next to a flexible fiber-optic bronchoscope, guided by diagnostic FOB. Initially, a Polyflex stent of 8 mm × 2 cm was deployed in the left lower lobe bronchus and expanded against segmental bronchi, resulting in a slight decrease in bleeding. This was followed by placement of an Ultraflex stent of 14 mm × 6 cm, extending from the proximal left main-stem bronchus to the left upper lobe bronchus, thus blocking the orifice of the left lower lobe bronchus. Following this procedure, bleeding into the proximal airways stopped, the patient was extubated and was able to undergo palliative radiotherapy. No recurrence of hemoptysis was reported in the last 4 months of the patient’s life [88].

**Endobronchial Stent Tamponade**

Successful tamponade and isolation of the bleeding site in a patient with massive hemoptysis has been achieved recently by the placement of two covered self-expanding airway stents. Bleeding originated from a left lower lobe cavitary non-small-cell lung cancer, and was confirmed by diagnostic FOB. Initially, a Polyflex stent of 8 mm × 2 cm was deployed in the left lower lobe bronchus and expanded against segmental bronchi, resulting in a slight decrease in bleeding. This was followed by placement of an Ultraflex stent of 14 mm × 6 cm, extending from the proximal left main-stem bronchus to the left upper lobe bronchus, thus blocking the orifice of the left lower lobe bronchus. Following this procedure, bleeding into the proximal airways stopped, the patient was extubated and was able to undergo palliative radiotherapy. No recurrence of hemoptysis was reported in the last 4 months of the patient’s life [89].

**Endobronchial Airway Blockade**

**Silicone Spigot**

Endobronchial placement of a silicone spigot has proved adequate for temporary control of bleeding, allowing patients to stabilize before endovascular embolization. Dutau et al. [90] reported the first case of its successful use in a young woman presenting with massive hemoptysis. A rigid bronchoscope initially allowed aspiration of blood and removal of clots in the right bronchial tree, following which bleeding started anew at the posterior segment of the right upper lobe. Cold saline and topical vasoactive agents were only partially effective in controlling bleeding, which prompted other treatment options. A flexible biopsy forceps was introduced through a flexible fiber-optic bronchoscope, with its distal end out of the bronchoscope, grasping a 6-mm silicone spigot. The flexible fiber-optic bronchoscope was then inserted into the rigid bronchoscope, and advanced towards the posterior segment of the right upper lobe, where the spigot was left in place under direct vision (fig. 2). Following this procedure, the patient underwent BAE, and the spigot was removed 2 h later.
Bronchoscopy-Guided Topical Hemostatic Tamponade

Recently, topical hemostatic tamponade therapy, using oxidized regenerated cellulose mesh, a sterile kitted fabric, has been tried successfully in patients with life-threatening hemoptysis [16]. This procedure was performed in patients with persistent hemorrhage despite bronchoscopic wedging into the bleeding bronchus, cold saline lavage and local administration of epinephrine. The oxidized regenerated cellulose mesh was grasped with a biopsy forceps that had already been inserted into a flexible fiber-optic bronchoscope. It was then pulled back into the bronchoscope and introduced into the bleeding airway, ranging from lobar to subsegmental bronchi. An immediate arrest of the hemorrhage was achieved in 56 of 57 (98%) patients, who remained free of hemoptysis for the first 48 h. The only patient who had persistent hemoptysis despite hemostatic tamponade therapy underwent a successful surgical intervention. Mild to moderate bleeding (<30–100 ml) recurred in 6 subjects (10.5%) 3–6 days after the procedure. BAE was performed in all 6, but failed to control bleeding in 2 of them. These 2 patients subsequently underwent repeat hemostatic tamponade therapy. Postobstructive pneumonia was observed in 5 patients, mainly in those who underwent tamponade of lobar bronchi (4 subjects). A subgroup of patients (n = 14) underwent repeat bronchoscopy 3–4 weeks after the procedure, and none of them suffered a recurrence of bleeding. In a mean follow-up of 10 months, no hemoptysis-related death was reported. It is worth noting that this approach is not suitable for proximal sites of bleeding such as the trachea, or in patients who cannot tolerate occlusion of the bleeding airway [91]. Moreover, concerns were expressed regarding the risk of late recurrence of hemoptysis since the oxidized regenerated cellulose mesh is absorbed [91].

Endobronchial Sealing with Biocompatible Glue

Endobronchial application of n-butyl cyanoacrylate, a biocompatible adhesive that solidifies on contact with humidity, has proved effective in controlling mild hemoptysis [92]. In a series of 6 patients with prolonged hemoptysis...

Fig. 2. Endobronchial embolization of the posterior segment of the right upper lobe with a silicone spigot as a temporary treatment for massive hemoptysis.
sis (>7 days) despite conservative treatment, this material was injected into the bleeding airway through a catheter via a flexible fiber-optic bronchoscope. The bronchoscope was removed, and reintroduced few minutes later to check for persistent bleeding. The procedure was repeated until hemostasis was achieved. In all 6 patients, bleeding stopped following the procedure. A mild cough was reported by all subjects, as well as transient expectoration of granular material. Recurrence of bleeding was observed in 1 patient the same day, but was successfully managed by a repeat procedure. No other recurrences were noted during a follow-up of 70–250 days, except for 1 patient with known bronchiectasis, who experienced mild bleeding 1 month after the procedure and was treated conservatively. To our knowledge, no reports have described the use of this approach in massive hemoptysis.

**Laser Photocoagulation**

Nd-YAG laser has been employed since 1982, and was first introduced by Dumon et al. [93]. Nd-YAG laser coagulation can be an effective treatment option for hemoptysis when the source of bleeding is bronchoscopically visible (fig. 3). It allows photocoagulation of the bleeding mucosa with resulting hemostasis, and can help achieve photoresection and vaporization of the underlying lesion, thus providing a definitive approach to hemoptysis management [1, 94]. However, the use of laser photocoagulation for massive bleeding has provided mixed results [94, 95]. Edmondstone et al. [94] described successful management of life-threatening hemoptysis with bronchoscopic laser photocoagulation. Infrared light was applied on a hemorrhagic tumor in the right mainstem bronchus with complete hemostasis. On the other hand, Shankar et al. [95] failed to control an episode of profuse bleeding using this approach on a hemangiopericytoma in the lower trachea, and opted instead for tamponade of the bleeding area before elective surgical resection.

With regard to malignant tracheobronchial tumors, the main indications for endobronchial laser photocoagulation are endoluminal tumors presenting with symptom-
The bleeding was often observed in patients with bronchial tumors. Repeat courses of laser treatment were successful in case of relapse. Failure of laser therapy to stop the bleeding was often observed in patients with bronchial APC therapy. Bleeding was severe (>200 ml/24 h) in 6 patients, moderate (>50–200 ml/24 h) in 23 patients, and mild (≤50 ml/24 h) but persisted for over a week in 27 patients. Airway hemorrhage stopped immediately after the procedure in all patients with an endoluminal source of bleeding. No recurrence of bleeding was observed on a mean follow-up period of 97 days. However, bleeding originating from a new endobronchial site was observed in 3 patients, and was treated successfully by APC. In 1 patient, the source of bleeding was not within the reach of the bronchoscope, and therefore BAE was performed after failure of APC. All patients had malignant underlying diagnoses, except for 2 patients who had telangiectasia and bronchiectasis as the source of bleeding.

In a recent case report, a heart transplantation patient with recurrent massive hemoptysis was unsuccessfully treated with BAE. Subsequent evaluation at a referral center revealed endobronchial hemorrhagic polyoid lesions which were treated with APC until dessication, with no further recurrence of bleeding in the 10 months of follow-up [99].

Although several other reports have described resolution of hemoptysis following APC treatment of endoluminal targets, bleeding episodes in most cases were mild to moderate, with benign underlying causes, namely endobronchial hemangiomas and endobronchial endometriosis with catamenial hemoptysis [101–103].

**Electrocautery**

Electrocautery to control hemoptysis has been mostly anecdotal. In a study of 56 patients with advanced lung cancer or benign tumors, control of hemoptysis using endobronchial electrocautery was achieved in 75% of the cases [104]. Sutedja et al. [105] reported successful management of hemoptysis in 4 patients treated with electrocautery for locally advanced tracheobronchial malignancies, without recurrence for the following 4 weeks. It is worth noting, however, that the magnitude of bleeding was not specified.

**Other Treatments: Cryotherapy and Brachytherapy**

Endobronchial cryotherapy has proved effective to manage hemoptysis in patients with inoperable endoluminal malignancies [106–108]. In fact, freezing has been shown to cause vasoconstriction and development of microthrombi in venules and capillaries, which might explain the efficacy of cryotherapy for obtaining hemostasis [109]. In addition, successful removal of blood clots has been achieved using this approach [110]. However, because of its delayed effect, cryotherapy has no role in the management of massive hemoptysis [46].

Brachytherapy, although effective as a palliation treatment for hemoptysis in advanced lung cancer, is not a treatment option either for massive bleeding [111].
Bronchial Artery Embolization

BAE for the management of hemoptysis was first performed by Remy et al. [112] in 1973. The first large series published by this group in 1977 reported the outcome of 104 patients who underwent embolization of bronchial and nonbronchial arteries for the control of massive or recurrent hemoptysis [113]. Forty-nine patients were treated during active hemoptysis, with immediate arrest of bleeding in 41 patients. Six of these patients had recurrent episodes of bleeding 2–7 months after the initial procedure. Since then, BAE has been widely used to control massive hemoptysis, as a temporary measure to stabilize patients before surgical resection or medical treatment (antibiotics/antituberculous drugs) or as a definitive therapeutic approach in patients who refuse surgery, who are not considered as candidates for surgery (poor lung function, bilateral pulmonary disease, comorbidities), or patients in whom surgery is contraindicated (fig. 4).

Immediate control of hemoptysis with BAE has been reported in 57–100% of patients [12, 26, 44, 113–121]. This wide range of success rates across studies can be partially attributed to heterogeneity with regard to analysis of results [122]. In some studies, patients in whom the procedure was attempted, even though it was not completed because of technical difficulties, were accounted for in the final calculations of success rates [12, 26, 114, 122]. This intent-to-treat analysis might explain the lower success rates in the study by Mal et al. [12]. In some of the other series reporting higher success rates, no details were provided with regard to patients in whom BAE was initiated but not completed [117–119]. Reasons for abandoning the procedure after an initial attempt were failure to cannulate the bronchial artery or to achieve a stable catheter position within its lumen, and visualization of a spinal artery branch arising from a bronchial artery [12, 114, 118]. However, since the mid 1990s, a 'super-selective' technique with the use of a 3-french microcatheter to cannulate smaller caliber vessels has been developed and widely employed. This technique allows a more stable position within the bronchial circulation, and permits cannulation of a bronchial artery distally to the origin of a spinal branch, therefore avoiding neurological complications [117].

Although bleeding recurrence after BAE has been described in 10–29% of patients at 1-month follow-up [12, 26, 114], the procedure can be repeated safely [114]. Barben et al. [121] reported the need of a second embolization in 55% (11/20) of their cystic fibrosis patients, with a median time interval of 4 months between the first and second procedures. Recurrence of hemoptysis may be due to incomplete embolization of the bronchial vessels, recanalization of the embolized arteries, presence of nonbronchial systemic arteries, or development of collateral circulation in response to continuing pulmonary inflammation [12, 114, 115, 123]. Therefore, some authors advocate thorough embolization, including embolization of nonbronchial systemic arteries which might have contributed to the bleeding episode, in addition to careful evaluation and treatment of the underlying pulmonary condition. It has been postulated that recurrence rates may be related to the etiology of hemoptysis. Several studies have found that bleeding anew after BAE occurred more often in patients with bronchogenic carcinomas [26, 114, 118]. Others have reported higher rates of recurrence in patients with aspergillomas [26, 124].

It is worth noting that persistent or recurrent hemoptysis following BAE may also suggest bleeding of PA origin [28, 125], a finding that could have been missed or misinterpreted on radiological work-up (e.g. multidetec-
tor CT). If this diagnostic entity is confirmed, PA embolization should be performed to ensure timely control of hemoptysis. Unlike endovascular treatment, however, surgical management excludes the risk of recurrent PA bleeding [126]. This is particularly true for unpredictable massive bleeding episodes in the context of necrotizing lung infections such as mycetomas, where resection is the only definitive treatment strategy for recurrent hemoptysis. The majority of patients with aspergilloma will bleed anew after some time if they are not treated surgically. BAE is, therefore, a temporary treatment strategy for massive hemoptysis in such patients. Aspergilloma will almost always require surgery following urgent BAE. Massive hemoptysis in patients with aspergilloma has been associated with a 25–30% mortality rate [128]. In recent studies, surgical resection of aspergillomas in patients with severe hemoptysis has been successfully achieved with a low intraoperative mortality rate [128, 129]. PA hemorrhage in the context of resectable lung tumors is another indication for prompt surgical resection following initial endovascular management [46].

On the other hand, pulmonary arteriovenous malformation – another well-recognized cause of massive hemoptysis of PA origin – has been shown to respond favorably to PA embolization with a satisfactory long-term outcome, therefore avoiding surgical resection. In a study by Haitjema et al. [130], where 92 pulmonary arteriovenous malformations in 32 patients were treated by coil embolization, significant improvement in arterial oxygen tension and shunt fraction were observed. Interestingly, recannalization of embolized vessels occurred in only 2 patients after 22 and 28 months. The mean follow-up was 25 months.

Procedure-related complications are rare (<5%) and include transient pyrexia and chest pain [12, 114], transient dysphagia [114], groin hematoma [114], subintimal dissection or perforation of arteries by the guidewire [12, 114], and transient or sometimes permanent neurological deficits [12, 14, 26, 49]. Although neurological complications are the most dreaded adverse effects, their incidence has significantly decreased since the wide use of the 'super-selective' technique which enables distal cannulation of the target vessel, beyond the origin of spinal branches [123].

Surgery

Emergency surgery for the management of massive hemoptysis has been gradually abandoned because of the high morbidity and mortality ranging between 20 and 30% [7, 8, 131] and the advent of safe and effective alternative endovascular techniques. In addition, surgical resection is not an option for patients with poor functional status, moderate to severe lung function impairment, bilateral pulmonary disease or other comorbidities.

Currently, surgery is mainly reserved for cases of technical failure of arteriography as outlined above [26, 44], early or repeated recurrences of hemoptysis despite BAE [26, 44], or in extreme situations where the amount of bleeding or the patient’s cardiopulmonary status are deemed life-threatening and do not allow transfer to an interventional radiology suite or any related delays in management [1]. In a recent study by Ong and Eng [13], only 4 of 31 patients (12%) underwent emergent surgical procedures for the control of bleeding after failure of repeated BAE procedures, with an overall in-hospital mortality rate of 13%. A similar approach was used by Farouch et al. [26], who only treated 23 of 196 (12%) patients with surgical resection. Reported intensive care unit and hospital mortality rates were 4 and 8%, respectively. In a recent study, where surgical management of massive hemoptysis was avoided in the first 48 h and conducted only after technical failure or early relapse following BAE, lower in-hospital mortality (0%) and surgical morbidity (18%) rates were observed in comparison with earlier studies favoring surgery as first-line therapy [5].

Surgery also remains the strategy of choice for the management of massive hemoptysis caused by diffuse and complex arteriovenous malformations, iatrogenic PA rupture, chest trauma, and mycetoma not responding to other therapeutic strategies, or associated with recurrent life-threatening hemoptysis as outlined above [59]. Bronchovascular fistulas with ensuing massive bleeding – most often encountered following surgery, local infection, associated with vascular aneurysms, and less frequently following lung transplantation surgery – are also managed by surgical repair once the patient is stabilized. However, endovascular stent grafting has been performed since 1994 for aortobronchial fistulas with satisfactory results, and lower mortality and complication rates [132–135].

**Therapeutic Strategy Algorithm**

Although there is no consensus on a precise definition of massive hemoptysis, it should always be regarded as a life-threatening condition requiring timely management through efficient multidisciplinary efforts and collabora-
tion (fig. 5). The initial approach consists of assessing and stabilizing the patient's condition through effective airway protection and volume resuscitation. Rigid bronchoscopy is the most effective initial procedure in patients with massive hemoptysis associated with hemodynamic compromise and respiratory instability, as it is the only means to efficiently clear the airways from clotted blood and secretions, to isolate the nonaffected lung, thereby preserving adequate ventilation, and to perform rapid and efficient tamponade of the bleeding lobar bronchus. In addition, introduction of a flexible fiber-optic bronchoscope through the rigid tube might allow better inspection of the upper lobes and peripheral airways. A chest radiograph might provide complementary information. A CT scan of the chest requires transfer to the radiology suite, thus delaying patient care. It should be

**Fig. 5.** Algorithm of multidisciplinary management of massive hemoptysis. ICU = Intensive care unit; ADH = antidiuretic hormone; ORC mesh = oxidized regenerated cellulose mesh. MDCT = multidetector CT. 1 Exclusively for visible endoluminal lesions.
performed, however, once patients are stabilized, in cases where neither chest radiograph nor bronchoscopy has provided diagnostic clues regarding the site or etiology of bleedin...g in our era of noninvasive therapy, endobronchial management strategies have not been validated by randomized controlled trials. They can be initiated for the early management of massive hemoptysis, until more definitive endovascular or surgical therapies become available. In a recent trial, airway clearance with rigid bronchoscopy before surgical resection contributed to lower in-hospital mortality and lower surgical morbidity [5]. Early bronchoscopic management can therefore improve patient outcome, even as a temporary measure to control bleeding. In some cases, however, bronchoscopic techniques might provide long-lasting hemostasis in patients not deemed suitable for other treatment strategies. Currently, BAE is considered a first-line definitive procedure for managing hemoptysis, with the few exceptions outlined above. Surgery, as a salvage strategy, is indicated after failure of BAE and is associated with better survival when performed in a nonurgent setting.

References

Massive Hemothorax and Bronchial Artery Embolization: A Systematic Review

Jongsuk Park, Seung-Min Seo, Yong-Joong Kim, Hye-Eun Lee, Eun-Soo Song

1. Introduction
2. Materials and Methods
3. Results
4. Discussion
5. Conclusion

References

Massive Hemothorax: Management Options

Jongsuk Park, Seung-Min Seo, Yong-Joong Kim, Hye-Eun Lee, Eun-Soo Song

1. Introduction
2. Evaluation of Massive Hemothorax
3. Management Options
4. Conclusion

References

Massive Hemoptysis: Bronchoscopy in Diagnosis and Management

Jongsuk Park, Seung-Min Seo, Yong-Joong Kim, Hye-Eun Lee, Eun-Soo Song

1. Introduction
2. Diagnosis of Massive Hemoptysis
3. Bronchoscopy in Massive Hemoptysis
4. Management of Massive Hemoptysis

References

Massive Hemorrhage: Management Options

Jongsuk Park, Seung-Min Seo, Yong-Joong Kim, Hye-Eun Lee, Eun-Soo Song

1. Introduction
2. Evaluation of Massive Hemorrhage
3. Management Options
4. Conclusion

References

Massive Hemorrhage: Management Options

Jongsuk Park, Seung-Min Seo, Yong-Joong Kim, Hye-Eun Lee, Eun-Soo Song

1. Introduction
2. Evaluation of Massive Hemorrhage
3. Management Options
4. Conclusion

References


